薄壁组织
中枢神经系统
脑脊液
不利影响
钙调神经磷酸酶
流出
生物
药理学
泊沙康唑
医学
病理
曲菌病
烟曲霉
脑膜炎
氟康唑
药代动力学
免疫学
曲霉
两性霉素B
伏立康唑
血脑屏障
真菌病
癌症
黑色素瘤
心脏毒性
脑室炎
抗生素
亲脂性
渗透(战争)
毛霉病
作者
Francelise Bridi Cavassin,Emanuel Rocha Nery,Leonardo Luder Corrêa,Pedro Ziebel da Silva,Brenda Camila Reck de Oliveira,Filipe Prohaska-Batista,Flávio Queiroz‐Telles,Marcello Mihailenko Chaves Magri
摘要
Invasive fungal infections (IFIs) involving the central nervous system (CNS) represent a critical challenge, with mortality of 50% or more in cerebral aspergillosis, mucormycosis, fusariosis and cryptococcal meningitis, and pharmacokinetic (PK) access restricted by the blood-brain barrier (BBB). This review analyzes the clinical performance and parenchymal penetration of isavuconazole (ISA), a second-generation triazole. ISA exhibits linear PK, a cyclodextrin-free intravenous formulation, and high tissue affinity, favored by moderate lipophilicity (experimental logP 2.56) and in vitro inhibition of P-glycoprotein and breast cancer resistance protein (BCRP) efflux transporters. Experimental evidence from animal models shows brain-to-plasma ratios of 0.42 to 1.8, indicating efficient BBB crossing. Human biopsy data show a fundamental PK dichotomy. While cerebrospinal fluid concentrations are restricted (about 1% of plasma), levels in fungal abscesses and inflamed parenchyma reach up to 5.11 mg/L, exceeding the minimum inhibitory concentration reported for Aspergillus fumigatus in those cases. Clinically, ISA was associated with a response in 70% of first-line (n = 10) and 73% of salvage-treated patients (n = 30) with cerebral aspergillosis, and 82% of 28 patients with CNS-only coccidioidomycosis improved or stabilized. Meta-analyses suggest fewer drug-related adverse events and, in randomized subgroups, fewer hepatobiliary events compared with voriconazole, although moderate cytochrome P450 3A4 inhibition warrants monitoring of calcineurin and mechanistic target of rapamycin (mTOR) inhibitors in transplant recipients. ISA is a strategic option for high-complexity CNS-involving IFIs, serving as a therapeutic alternative in salvage and prolonged-maintenance settings, though first-line use in CNS infection awaits confirmation from randomized trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI